Company profile
INVIVYD, INC.
NASDAQ:IVVDBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IBRAMVIBART | phase3 | — | 2 | active |
| ADINTREVIMAB | phase2_3 | — | 2 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06523153 | phase1 | active_not_recruiting | 2024-08-28 | 2025-05-01 | Invivyd, Inc. | A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants |
| NCT06039449 | phase3 | completed | 2023-09-08 | 2024-11-19 | Invivyd, Inc. | A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2 |
| NCT05791318 | phase1 | completed | 2023-03-28 | 2024-05-08 | Invivyd, Inc. | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants |
| NCT04859517 | phase2_3 | terminated | 2021-04-27 | 2022-11-04 | Invivyd, Inc. | Evaluation of ADG20 for the Prevention of COVID-19 |
| NCT04805671 | phase2_3 | terminated | 2021-07-26 | 2022-02-10 | Invivyd, Inc. | Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19 |
FDA applications (0)
No records yet.